3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
6
Phase 3
4
Phase 1
4
Phase 1/2
2
Phase 4
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
4
Neurotoxicity Syndromes
1
Neoplasm Metastasis
1
Drug-Related Side Effects and Adverse Reactions
1
Interventions
Zoledronic Acid
5
Bevacizumab
3
exemestane
2
Therapeutics
2
Standard of Care
2
Pamidronate
2
Oxaliplatin
2
Misoprostol
2
Magnetic Resonance Spectroscopy
2
Letrozole
2
Ibandronic Acid
2
Fulvestrant
2
Fluorouracil
2
Cetuximab
2
Capecitabine
2
vandetanib
1
palbociclib
1
liposomal doxorubicin
1
huaier
1
eribulin
1
enzalutamide
1
darolutamide
1
cabozantinib
1
aldesleukin
1
abemaciclib
1
Vindesine
1
Trastuzumab
1
Sugars
1
Stents
1
Specimen Handling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Neoplasm Metastasis
×
eribulin
×
Clear all
NCT01961544
2016-10-07
ESKIMO
Eisai Inc.
Phase 4
Completed
101 enrolled
6 charts